Processing

Please wait...

Settings

Settings

Goto Application

1. EP2206512 - Increase of interferon-beta for anti-virus therapy for respiratory diseases

Office European Patent Office
Application Number 10161661
Application Date 07.03.2005
Publication Number 2206512
Publication Date 14.07.2010
Publication Kind A3
IPC
A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
A61K 9/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
12Aerosols; Foams
A61K 31/57
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
CPC
A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61K 38/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons ; [IFN]
215IFN-beta
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
Applicants UNIV SOUTHAMPTON
Inventors DAVIES DONNA ELIZABETH
WARK PETER ALEXANDER BLANCH
HOLGATE STEPHEN
JOHNSTON SEBASTIAN L
Designated States
Priority Data 05708482 07.03.2005 EP
0405634 12.03.2004 GB
Title
(DE) Erhöhung von Interferon-Beta zur Behandlung von Atemwegserkrankungen
(EN) Increase of interferon-beta for anti-virus therapy for respiratory diseases
(FR) Augmentation de l'interferon-beta pour le traitement des maladies respiratoires
Abstract
(EN)
The present invention provides an agent selected from (a) an agent that increases endogeneous interferon beta (IFN-²) expression in the lung; or (b) a polynucleotide which is capable of expressing such an agent for use in the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease (COPD), wherein said treatment is by airway delivery of said agent.

(FR)
L'invention concerne l'utilisation de IFN-$g(b), d'un agent qui augmente l'expression de IFN-$g(b), ou d'un polynucléotide capable d'exprimer IFN-$g(b) ou dudit agent pour la fabrication d'un médicament destiné au traitement de l'exacerbation induite par le rhinovirus d'une maladie respiratoire choisie parmi l'asthme et la bronchopneumopathie chronique obstructive, ledit traitement s'opérant par administration dudit médicament par voie aérienne, par exemple par l'utilisation d'un nébuliseur aérosol.